Evidence map›Paper›PMID 32013416›Full record

ArticleJournal of the American Society for Mass Spectrometry2020

Quantitation of Urinary Acylcarnitines by DMS-MS/MS Uncovers the Effects of Total Body Irradiation in Cancer Patients.

Nicholas B Vera, Stephen L Coy, Evagelia C Laiakis, Albert J Fornace, Michelle Clasquin, Christopher A Barker, Jeffrey A Pfefferkorn, Paul Vouros

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Society for Mass Spectrometry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Nicholas B VeraPfizer Global Research and Development, Cambridge Laboratories, Pfizer, Inc., Cambridge, Massachusetts 02139, United States.ORCID http://orcid.org/0000-0003-2917-7523
Stephen L CoyDepartment of Chemistry and Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States.ORCID http://orcid.org/0000-0002-6991-683X
Evagelia C LaiakisDepartment of Oncology, Georgetown University, 3700 O Street NW, Washington, DC 20057, United States.ORCID http://orcid.org/0000-0002-4924-9013
Albert J FornaceDepartment of Oncology, Georgetown University, 3700 O Street NW, Washington, DC 20057, United States.
Michelle ClasquinPfizer Global Research and Development, Cambridge Laboratories, Pfizer, Inc., Cambridge, Massachusetts 02139, United States.
Christopher A BarkerDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, United States.
Jeffrey A PfefferkornPfizer Global Research and Development, Cambridge Laboratories, Pfizer, Inc., Cambridge, Massachusetts 02139, United States.
Paul VourosDepartment of Chemistry and Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States.
Northeastern University · USGeorgetown University · USPfizer (United States) · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Sample Engineering CoreU19AI067773 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FORNACE, ALBERT J · 2005 to 2024
$105.4M
Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI Louis M Weiner · 1990 to 2026
$71.5M
PA-12-149: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp): Metabolomic biomarkers and instrumentation for assessment of radiation injury,R01AI101798 · NIAID · GEORGETOWN UNIVERSITY · PI FORNACE, ALBERT J · 2012 to 2016
$2.2M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA051008NIAID NIH HHS R01 AI101798NIAID NIH HHS U19 AI067773
6 · The paper itself

Abstract

Acylcarnitines have been identified in human and animal metabolomic-profiling studies as urinary markers of radiation exposure, a result which is consistent with their cytoprotective effects and roles in energy metabolism. In the present work, a rapid method for quantitation of the more abundant acylcarnitines in human urine is developed using a valuable set of samples from cancer patients who received total body irradiation (TBI) at Memorial Sloan Kettering Cancer Center. The method uses solid-phase extraction (SPE) processing followed by differential mobility spectrometry (DMS with ethyl acetate modifier) tandem mass spectrometry (ESI-DMS-MS/MS) with deuterated internal standards. The analyzed human urine samples were collected from 38 individual patients at three time points over 24 h during and after the course of radiation treatment, a design allowing each patient to act as their own control and creatinine normalization. Creatinine-normalized concentrations for nine urinary acylcarnitine (acyl-CN) species are reported. Six acyl-CN species were reduced at the 6 h point. Acetylcarnitine (C2:0-CN) and valerylcarnitine (C5:0-CN) showed recovery at 24 h, but none of the other acyl-CN species showed recovery at that point. Levels of three acyl-CN species were not significantly altered by radiation. This rapid quantitative method for clinical samples covers the short- and medium-chain acylcarnitines and has the flexibility to be expanded to cover additional radiation-linked metabolites. The human data presented here indicates the utility of the current approach as a rapid, quantitative technique with potential applications by the medical community, by space research laboratories concerned with radiation exposure, and by disaster response groups.

Indexed as

AnimalsBiomarkersCarnitineHumansNeoplasmsPilot ProjectsRats, Sprague-DawleyTandem Mass SpectrometryWhole-Body IrradiationacylcarnitineBiomarkersCarnitine

Identifiers

PMID32013416
PMCPMC7489307
OpenAlexW3003313423

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.